Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Research indicates that extended PSMA therapy is safe and effective for patients with prostate cancer.

2.

Radionuclide-Containing Combo Slows Metastatic Prostate Cancer, Improves Survival

3.

CAR T cells improve patients' quality of life: a study

4.

No increased risk of childhood cancer near UK nuclear sites, study finds

5.

Newly identified T-cell subtype may explain treatment-resistant childhood leukemia


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot